Tetrahedron Letters
Synthesis of b-D-GalNAc(4,6-diS)(1–4)[
a-L-Fuc(2,4-diS)(1–3)]-b-D-GlcA,
a novel trisaccharide unit of chondroitin sulfate with a fucose branch
b
b
a
Jun-ichi Tamura a,b, , Haruna Tanaka , Ayumi Nakamura , Naoko Takeda
⇑
a Department of Chemistry and Biotechnology, Graduate School of Engineering, Tottori University, Koyamacho-Minami 4-101, Tottori 680-8552, Japan
b Department of Regional Environment, Faculty of Regional Sciences, Tottori University, Koyamacho-Minami 4-101, Tottori 680-8551, Japan
a r t i c l e i n f o
a b s t r a c t
Article history:
Novel glycosaminoglycans isolated from the body wall of sea cucumbers consist of chondroitin sulfates
like polysaccharides. We have synthesized a representative repeating trisaccharide composed of a
Received 1 April 2013
Revised 8 May 2013
Accepted 13 May 2013
Available online 24 May 2013
chondroitin backbone having a fucose (Fuc) branch at O-3 of glucuronic acid (GlcA), b-
D-GalNAc(4,6-
diS)(1–4)[ -Fuc(2,4-diS)(1–3)]-b- -GlcA, in a stereocontrolled manner. Regiospecific sulfation at O-
a
-L
D
4,6 and O-2,4 of the N-acetylgalactosamine (GalNAc) and Fuc residues, respectively, was successfully
achieved.
Keywords:
Ó 2013 Elsevier Ltd. All rights reserved.
Chondroitin sulfate
Glycosaminoglycan
Sea cucumber
Glycosylation
Chondroitin sulfates (CSs), important glycosaminoglycans, have
numerous biological activities represented by neuronal growth
control.1,2 Many animals produce CSs as linear polysaccharides
Based on the retrosynthetic analysis depicted in Scheme 1, we
planned the fucosylation of a suitably protected chondroitin disac-
charide precursor. Subsequent sulfation at specific positions was
expected to yield the target compound 1.
composed of a repeating disaccharide unit, -3)-b-
D-GalNAc(1-4)-
b- -GlcA(1-, some hydroxyl groups of which are often sulfated. A
D
The glycosyl acceptor for obtaining the disaccharide was syn-
thesized as shown in Scheme 2. First, the known diol (2)7 was
mono-acetylated with regulated amounts of reagents. The yield
was sufficient (73%), but no regioselectivity was shown and the
regioisomeric monoacetates (3a and 3b) could not be separated.
We tried to benzylate the mixture at the residual positions. To
our surprise, a sole compound (4) benzylated only at O-2 was
obtained in 97% yield. We rationalized that the result was due to
the basicity of Ag2O which moved the acetyl group to O-3 followed
by regioselective benzylation at O-2. Similar migration was not
observed in the case of the methylbenzoyl (MBz) analogue. The
acetate (4) was successfully converted to methylbenzoate (6) via
5 in 85 and 97% yield, respectively. The benzylidene acetal of 6
was removed in 81% yield and the primary alcohol was selectively
protected with TBDPS to yield the glycosyl acceptor (8) in 87%
yield. Galactosyl imidate (9)8 was stereoselectively coupled with
8 in the presence of BF3ÁOEt2 in toluene at À50 °C to afford the de-
sired disaccharide (10) in 40% yield (Scheme 2). The levulinoyl
group of 10 was removed with H2NNH2ÁAcOH and the liberated
O-3 was benzylated with BnBr in the presence of Ag2O to give 12
in 98 and 79% yield, respectively. Alternatively, we also adopted
galactosyl imidate (16) masked with a benzyl group at O-3 which
was obtained from the corresponding hemiacetal (15)9 in 83% yield
unique fucosyl chondroitin sulfate (FCS) has been isolated from
sea cucumber having a fucose branch at O-3 of the GlcA moiety
with a variety of sulfation patterns at GalNAc and Fuc residues.3
Di- or trimeric fucose branches have also been described.4 FCS
inhibits thrombin by activating heparin cofactor II, and also acti-
vates factor XII.5 FCS shows anticoagulant activities even when
delivered orally.6 This remarkable activity is completely different
from heparin which is injected intravenously. Medicines having
anticoagulant activities are available but can have significant side
effects. The sulfation patterns and the role of the fucosyl residues
of FCS might be closely related to its biological activities. This
prompted us to synthesize the repeating unit of FCS in order to elu-
cidate the relationship between its biological activities and facile
structure so as to develop an alternative type of medicine. Here
we describe the first synthesis of the FCS trisaccharide, b-D-Gal-
NAc(4,6-diS)(1–4)[a-L-Fuc(2,4-diS)(1–3)]-b-D-GlcA (1).
⇑
Corresponding author. Tel./fax: +81 857 31 5108.
0040-4039/$ - see front matter Ó 2013 Elsevier Ltd. All rights reserved.